- Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication.
- The RMAT designation further increases Amniofix's chances of being approved, and gives MDXG the opportunity to apply for early approval after the Phase 2b knee OA trial is completed.
- Based on the very positive results that the product has shown in treating a variety of musculoskeletal ailments, Amniofix will also likely receive approval for multiple indications beyond knee OA.
- Given the massive addressable market for Amniofix and the promising results the product has shown in treating knee OA and other conditions, we project multi-billions in peak sales for Amniofix.
- The wound care business is poised to re-accelerate over the coming quarters due to recent insurance and contract wins, as well as the launch of a new wound care product.
For further details see:
MiMedx: Raising Our PT To $31 On New Findings That Indicate Amniofix Will Be A Blockbuster, Game-Changing Osteoarthritis Treatment